Biotechnology · Boston, Massachusetts, United States
$4.05
+0.50% (+$0.02)2026-08-24
Smart-Money SignalNeutral · 43/100— Insiders are net sellers over 90 days (-$356K, 3 sales vs 1 buy)
Revenue$8.8M
Net Income-$16.2M
EPS$-0.29
Market Cap$389.3M
Price Performance
Historical data including institutional events
Company Profile
P
Paula Ragan
CEO & Executive Director
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses.
The company is headquartered in Boston, Massachusetts.
